@cindylaurenyan's peptide therapy claims need context

What did @cindylaurenyan actually say?

She's been injecting GHK-Cu at 2mg five times a week for roughly a year, cycling three months on, one month off. Her goals were elasticity and "preventative aging," not acne. She claims her skin looks bouncier, more even, and says her hair has improved too. She's not subtle about her enthusiasm: "I can't talk about it enough."

To her credit, she was specific about her protocol and honest that her skin was already clear. She's not claiming GHK fixed a disease. She's describing cosmetic and subjective changes over a long observation window. That's a more reasonable framing than most peptide content on TikTok, but it still comes with problems worth addressing.

Does the science back this up?

There's legitimate preclinical and in vitro evidence that GHK-Cu influences skin biology, but the human clinical data is thin, especially for injected systemic use at her dose and frequency.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has been studied primarily in topical form. Pickart and Margolina (2018, Cosmetics) reviewed decades of research showing GHK-Cu stimulates collagen synthesis, activates antioxidant enzymes, and modulates wound healing pathways in vitro and in animal models. A double-blind study by Leyden et al. (1994, Journal of the American Academy of Dermatology) found topical GHK-Cu improved skin laxity and fine lines versus vehicle control. That's topical, not subcutaneous injection.

For injected GHK-Cu specifically, the human evidence is close to nonexistent in peer-reviewed literature. The mechanism could theoretically work systemically, but bioavailability, distribution, and dose-response in humans are not established. Claiming injection produces the skin results she describes is extrapolating well beyond what's been tested.

What did they get wrong (or right)?

She got the general biology roughly right. GHK-Cu does appear to affect collagen and elastin remodeling pathways. Pickart's foundational work and subsequent in vitro studies give the compound scientific credibility that many peptides promoted on social media simply don't have.

What she got wrong, or at least dramatically overclaimed, is the leap from "this compound has interesting biology" to "my skin is bouncier because of this injection." A year of using one product with no control condition, no baseline photography protocol, and a beauty filter comparison is not evidence. Skin changes from aging, seasonality, hydration, sleep, stress, and a dozen other variables over 12 months. She can't isolate GHK-Cu as the cause.

Her hair claim is even less supported. While some animal studies and small trials suggest copper peptides may influence hair follicle cycling (Uno and Kurata, 1993, Journal of Investigative Dermatology), the evidence for systemic GHK-Cu improving human hair is not established in clinical trials. Asserting "best results" without any comparison condition is the kind of anecdote that sounds compelling and proves nothing.

What should you actually know?

GHK-Cu is one of the more scientifically interesting compounds in the peptide space, and it's not a complete fiction. But interesting preclinical data does not equal proven human benefit from injections. The studies that exist used topical application in controlled settings. Systematic reviews of copper peptides in dermatology, including work by Gorouhi and Maibach (2009, Skin Pharmacology and Physiology), note promising signals but call for larger, well-designed trials before strong conclusions.

There are also real safety considerations with subcutaneous injection of compounded peptides that a 221K-view TikTok glosses over entirely. Injection site reactions, sterility of compounded preparations, and copper toxicity at higher accumulative doses are not theoretical concerns. They are documented risks that require medical oversight.

• GHK-Cu's safety profile at her specific dosing frequency has not been characterized in published human trials.
• Subjective skin assessments without standardized photography or blinding are not reliable outcome measures.
• Any use of injectable peptides should involve a licensed clinician who can monitor for adverse effects.